

Dear Dr. Arthur Jurczynszyn,

I am back home and can send you all information in one organized email....Please find below the details regarding CAR-T therapy opportunity for R/R Multiple Myeloma patients.

Heart to Heart Global facilitates the collaboration between Sourasky Medical Center in Israel and the First Affiliated Hospital of Soochow University Suzhou, China; sending Multiple Myeloma patients for CAR-T cell therapy in China to Prof Fu ChengCheng, who presented her impressive data at the ASH. Currently we are expanding our activity to be multi-national and allowing MM patients from different countries to be treated with CAR-T cell therapy in China.

We provide the entire non-medical support and logistics for the patients and their families, before, during and after the therapy.

The patient cost for the entire process is about 85,000 US dollars.

Here is some information regarding the Prof. Fu and the Chinese hospital, the First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology.

The hospital and CAR-T company, treated more than 600 hematopoietic cancer patients and more than 75 MM patients, with great success - similar to the US companies. First Affiliated Hospital of Soochow University Suzhou, China is the hospital that will receive the patients. It is very well located in Shanghai Area, ranking among top 5, considered a pilot in CAR-T therapy clinical trials with extensive experience medical teams, scored Number One of the most important hematopoietic stem cell transplant centers in China, awarded as one of the 3 national clinical research centers by National Science and Technology Department and National Medical Products Administration (NMPA) and other authorities, leading in the comprehensive diagnosis and standardized treatments of hematological cancers and won the third St. Anthony-EMBT Achievement Award in 2015.

Prof. Fu ChengCheng, Deputy Director, Head of the Multiple Myeloma department at the hospital and is the PI for the CAR-T clinical trials. Please see some of her latest publications:

ASH 2019: # 578. Sequential CD19- and BCMA-Specific Chimeric Antigen Receptor T Cell Treatment for RRMM: Report from a Single Center Study: <https://ativsoftware.com/appinfo.php?page=Session&project=ASH19&server=eventpilot.us&id=129740> #ASH19

ASH 2019 / 1949 / Combined Infusion of Anti-CD19 and Anti-BCMA CART Cells after Early or Later Transplantation in the Front Line Was Superior to Salvage Therapy for High Risk MM: <https://ash.confex.com/ash/2019/webprogram/Paper131546.html>

653.MYELOMA: THERAPY, EXCLUDING TRANSPLANTATION | NOVEMBER 13, 2019. Sequential CD19- and BCMA-Specific Chimeric Antigen Receptor T Cell Treatment for RRMM: Report from a Single Center Study: [https://ashpublications.org/blood/article-abstract/134/Supplement\\_1/578/426457](https://ashpublications.org/blood/article-abstract/134/Supplement_1/578/426457)

Chengcheng Fu | EBMT 19 | CAR T-cell therapy in the front-line treatment of patients with high-risk multiple myeloma (March 2019): <https://multiplemyelomahub.com/medical-information/chengcheng-fu-ebmt-19-car-t-cell-therapy-in-the-front-line-treatment-of-patients-with-high-risk-multiple-myeloma>

ASH 2018, Tandem Autologous Transplantation and Combined Infusion of CD19 and BCMA-Specific CAR T-Cells for High Risk MM: <https://www.myeloma.org/videos/tandem-autologous-transplantation-and-combined-infusion-cd19-and-bcma-specific-car-t-cells>

As for the logistic support, Heart to Heart Global assist patients in logistics matters, including all needs to participate in the CAR-T clinical trials being conducted in the Chinese hospital, handle all the necessary logistics and assistance to the hospital team, the patient and his family before, during and after the CAR-T cell therapy. We also offer "medical escort" by an Israeli hemato-oncology specialist from Sourasky Medical Center (for an extra cost).

It could be a great opportunity for the benefit of MM patients who are in need of CAR-T cell therapy and cannot receive it elsewhere.

As for the process; once you have a patient that needs CAR-T cell therapy, please send the medical summary plus medical exams. We will check with Prof. Fu if the patient is eligible for the treatment and we will go from there.

Please note that also Lymphoma and Leukemia patients can be treated with CAR-T cell therapy at the same hospital. Cost is a little higher due to more anticipating complications.